In August 2009, the company was recognized as a national high-tech enterprise by the Ministry of Science and Technology.
In April 2009, the raw materials and tablets of Antofloxacin Hydrochloride, a national innovative drug with independent intellectual property rights, were obtained by the State Food and Drug Administration.
(SFDA) new drug certificate and production approval
In April 2008, the company's tablet and capsule production line passed GMP certification.
In 2007, the company's "Global" trademark was recognized as a famous trademark in Anhui Province.
In 2007, the company was once again recognized as a key high-tech enterprise in the national torch plan.
From June 2006 to February 2006, the company's nateglinide raw material drug production line passed GMP certification.
From June 5438, 2006 to February 2006, the company's large-capacity injection (glass bottle) workshop passed the national GMP certification.
In 2005, the company was recognized as a key high-tech enterprise of the National Torch Program through evaluation.
In 2005, the company's "Glucose Injection" series products were recognized as famous brand products in Anhui Province.
In June 2004, the company's eye drops, ear drops, syrup, mixture and oral liquid passed GMP certification.
In 2004, the second, third and fourth plastic bottle infusion production lines were completed and passed the national GMP certification at one time.
In 2002, the company's technology center was recognized as a provincial enterprise technology center.
In 2002, the first plastic bottle infusion production line in the province was built in the company's high-tech zone and passed the national GMP certification.
In 2002, the company was recognized by the Ministry of Science and Technology as a key high-tech enterprise of the National Torch Program.
In 200 1 year, the company was recognized as a high-tech enterprise in Anhui province.
In 200 1 year, the company won the Anhui Quality Management Award.
In 200 1 year, the company passed the ISO900 1:2000: 2000 certification.
In June 2000, 165438+ 10, the company was restructured into a joint-stock pharmaceutical enterprise.